Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K051007
    Device Name
    ACCU02 SYSTEM
    Manufacturer
    Date Cleared
    2005-06-16

    (57 days)

    Product Code
    Regulation Number
    868.5905
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    ACCU02 SYSTEM

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The AccuO2 System, which provides oxygen therapy on demand, based on continuous, non-invasive monitoring of oxygen saturation, is indicated for home use by adult Chronic Obstructive Pulmonary Disease (COPD) patients who are prescribed low-flow (0-3 L/min) supplemental oxygen via nasal cannula and USP portable oxygen.

    Device Description

    The AccuO2 System is a portable, battery-operated system consisting of a proprietary demand oxygen delivery module combined with a commercially available pulse oximeter module. The system is used with a standard nasal cannula and USP portable oxygen. The proprietary software in the AccuO2 demand oxygen delivery module is designed to deliver oxygen on inhalation only and to maintain the patients at an oxygen saturation (SpO2) level of 90% while conserving oxygen.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the MITI Corp. AccuO2 System, based on the provided text:

    Acceptance Criteria and Device Performance

    Acceptance CriteriaReported Device Performance
    Accurately and reliably detect each inhaled breathVerified by functional testing
    Actuate the valve correctlyVerified by functional testing
    Accurate pulse oximeter readingsVerified by functional testing; functions equivalently to commercially available pulse oximeters
    Accurate oxygen amount calculationsVerified by functional testing
    Maintain patients at or above 90% SpO2Demonstrated by clinical studies
    Not increase time patient spends in hypoxic state compared to commercially available devicesDemonstrated by clinical studies
    Meet performance objectives and comply with applicable FDA guidelines and standards (functional, environmental, and safety testing)Demonstrated by functional, environmental, and safety testing

    Study Details

    2. Sample size for the test set and data provenance:

    • Sample Size: Not explicitly stated in the provided abstract. The text only mentions "clinical testing was conducted to evaluate the ability to maintain patients at or above 90% SpO2 as designed."
    • Data Provenance: Not specified (e.g., country of origin). The studies appear to be prospective given they are evaluating the device's performance, but this is not explicitly stated as retrospective or prospective.

    3. Number of experts used to establish the ground truth for the test set and their qualifications:

    • Not specified. The document refers to the device maintaining SpO2 levels and not increasing hypoxic states, which are physiological measurements, not interpretationsrequiring expert consensus in the same way an imaging study would.

    4. Adjudication method for the test set:

    • Not applicable/Not specified. The assessment criteria are objective physiological measurements (SpO2 levels, detection of breaths, valve actuation, oxygen amount calculation) rather than subjective interpretations requiring adjudication.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance:

    • No. This is not an AI-assisted diagnostic imaging device that would typically involve human readers. The AccuO2 system is a demand oxygen delivery system with an integrated pulse oximeter. The clinical studies compare its performance against existing devices, not human interpretation with/without AI assistance.

    6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

    • Yes, implicitly. The functional testing and clinical studies described evaluate the device's performance directly, independent of continuous human intervention in its core functioning (e.g., detecting breaths, actuating valves, maintaining SpO2). The system's purpose is to automate oxygen delivery based on physiological inputs.

    7. The type of ground truth used:

    • Physiological measurements and objective device performance. The ground truth for the pulse oximeter's accuracy would likely be against a co-oximeter or arterial blood gas (ABG) analysis, though this is not explicitly detailed. For breath detection and valve actuation, the ground truth would be based on direct measurement of those events. For SpO2 maintenance, the ground truth is the patient's actual oxygen saturation as measured by the device itself (and likely validated against a reference standard during development/testing).

    8. The sample size for the training set:

    • Not applicable/Not specified. This device predates the widespread use of deep learning and often doesn't involve a "training set" in the modern machine learning sense, as it relies on proprietary software for control rather than a learned model from a large dataset. The software logic would be developed and verified, not "trained."

    9. How the ground truth for the training set was established:

    • Not applicable/Not specified, for the reasons mentioned above. The "ground truth" for the device's operational logic would have been established through engineering design, physiological principles, and functional testing to ensure the software correctly implements the intended control strategy.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1